Tenaya Therapeutics Inc(TNYA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TNYA Tenaya Therapeutics Inc

Post-Mkt 01-21 18:06:57 EST

0.7159

+0.0137

+1.95%

盘后0.7300

+0.0141+1.97%

18:06 EST

High0.7330	Low0.6852	Vol2.12M
Open0.7190	D1 Closing0.7022	Amplitude6.81%
Mkt Cap155.00M	Tradable Cap147.36M	Total Shares216.51M
T/O1.51M	T/O Rate1.03%	Tradable Shares205.84M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TNYA","market":"US","secType":"STK","nameCN":"Tenaya Therapeutics Inc","latestPrice":0.7159,"timestamp":1769029200000,"preClose":0.7022,"halted":0,"volume":2121093,"hourTrading":{"tag":"盘后","latestPrice":0.73,"preClose":0.7159,"latestTime":"18:06 EST","volume":10157,"amount":7312.65769052,"timestamp":1769036807192,"change":0.0141,"changeRate":0.019695,"amplitude":0.033943},"delay":0,"changeRate":0.019510111079464446,"floatShares":205841252,"shares":216505900,"eps":-0.720885,"marketStatus":"Post-Mkt","change":0.0137,"latestTime":"01-21 18:06:57 EST","open":0.719,"high":0.733,"low":0.6852,"amount":1505734.50114009,"amplitude":0.068072,"askPrice":0.75,"askSize":3000,"bidPrice":0.7057,"bidSize":4849,"shortable":3,"etf":0,"ttmEps":-0.720885,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1769043600000},"marketStatusCode":4,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":0.7022,"preHourTrading":{"tag":"盘前","latestPrice":0.709,"preClose":0.7022,"latestTime":"09:29 EST","volume":43993,"amount":31400.126930399998,"timestamp":1769005769487,"change":0.0068,"changeRate":0.009684,"amplitude":0.025634},"postHourTrading":{"tag":"盘后","latestPrice":0.73,"preClose":0.7159,"latestTime":"18:06 EST","volume":10157,"amount":7312.65769052,"timestamp":1769036807192,"change":0.0141,"changeRate":0.019695,"amplitude":0.033943},"volumeRatio":0.755034,"impliedVol":2.0208,"impliedVolPercentile":0.7052},"requestUrl":"/m/hq/s/TNYA","defaultTab":"news","newsList":[{"id":"2602230886","title":"Tenaya Therapeutics: 2026 Clinical Milestones, FDA Pivotal Pathway, and Strengthened Balance Sheet Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2602230886","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602230886?lang=en_us&edition=fundamental","pubTime":"2026-01-10 00:35","pubTimestamp":1767976537,"startTime":"0","endTime":"0","summary":"William Blair analyst Sami Corwin has maintained their bullish stance on TNYA stock, giving a Buy rating today. Sami Corwin has given his Buy ratin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tenaya-therapeutics-2026-clinical-milestones-fda-pivotal-pathway-and-strengthened-balance-sheet-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tenaya-therapeutics-2026-clinical-milestones-fda-pivotal-pathway-and-strengthened-balance-sheet-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TNYA"],"gpt_icon":0},{"id":"2602370165","title":"Tenaya Therapeutics: 2026 as a Pivotal Year for TN-201 and TN-401 Clinical Readouts and Regulatory De-Risking Supporting a Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2602370165","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602370165?lang=en_us&edition=fundamental","pubTime":"2026-01-10 00:16","pubTimestamp":1767975376,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics today and set a price target of $3.00. Joseph Pantginis has...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tenaya-therapeutics-2026-as-a-pivotal-year-for-tn-201-and-tn-401-clinical-readouts-and-regulatory-de-risking-supporting-a-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tenaya-therapeutics-2026-as-a-pivotal-year-for-tn-201-and-tn-401-clinical-readouts-and-regulatory-de-risking-supporting-a-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TNYA"],"gpt_icon":0},{"id":"2602715243","title":"BRIEF-Tenaya Therapeutics Announces 2026 Strategic Priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2602715243","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602715243?lang=en_us&edition=fundamental","pubTime":"2026-01-09 22:01","pubTimestamp":1767967317,"startTime":"0","endTime":"0","summary":"BRIEF-Tenaya Therapeutics Announces 2026 Strategic Priorities Jan 9 (Reuters) - Tenaya Therapeutics Inc TNYA.O:TENAYA THERAPEUTICS ANNOUNCES 2026 STRATEGIC PRIORITIES AND ANTICIPATED MILESTONESTENAYA ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA9Y8BSS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNYA","BK4539","BK4139"],"gpt_icon":0},{"id":"2602237609","title":"Tenaya Therapeutics Outlines 2026 Strategy Including Regulatory Alignment for Gene Therapy Programs, Key Clinical Data Milestones, and Extended Funding Through Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2602237609","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602237609?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:30","pubTimestamp":1767965423,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Outlines 2026 Strategy Including Regulatory Alignment for Gene Therapy Programs, Key Clinical Data Milestones, and Extended Funding Through Mid-2027. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDLRQrYh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","SG9999014013.SGD","BK4539","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BKPKM429.USD","SG9999014021.USD","IE00B3QW5Z07.USD","BK4112","BK4139","SG9999014039.USD","LU2210149790.SGD","TNYA","BK4588","NDAQ","IE00BGHQF748.EUR","LU2095319765.USD"],"gpt_icon":0},{"id":"2602937986","title":"Tenaya Therapeutics Inc - Plans to Pursue Regulatory Alignment on Tn-201 in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602937986","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602937986?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:30","pubTimestamp":1767965400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA9Y8BSS:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","TNYA"],"gpt_icon":0},{"id":"2602798573","title":"Tenaya Therapeutics Inc - Plans to Pursue Regulatory Alignment on Tn-401 in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602798573","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602798573?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:30","pubTimestamp":1767965400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA9Y8BSS:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TNYA","BK4539","BK4139"],"gpt_icon":0},{"id":"2602089376","title":"Tenaya Therapeutics Inc - Raised $60 Mln in 4Q25 to Support Runway Through Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2602089376","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602089376?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:30","pubTimestamp":1767965400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA9Y8BSS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","TNYA"],"gpt_icon":0},{"id":"2602002376","title":"Tenaya Therapeutics - Expects to Report One-Year Cohort 1 Data & Early Cohort 2 Data From Ridge-1 Study of Tn-401 for Pkp2-Associated Arvc in H1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602002376","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602002376?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:30","pubTimestamp":1767965400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA9Y8BSS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","TNYA"],"gpt_icon":0},{"id":"2602795543","title":"Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2602795543","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602795543?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:30","pubTimestamp":1767965400,"startTime":"0","endTime":"0","summary":"Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 withLonger-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK-1 Trial of Adults with MYBPC3-Associated HCM Expects to Repor","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/09/3216081/0/en/Tenaya-Therapeutics-Announces-2026-Strategic-Priorities-and-Anticipated-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4531","BK4539","HCM","BK4585","BK4588","BK4139","TNYA"],"gpt_icon":0},{"id":"2600095819","title":"Tenaya Therapeutics Director David Goeddel Resigns Effective January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2600095819","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600095819?lang=en_us&edition=fundamental","pubTime":"2026-01-03 06:11","pubTimestamp":1767391869,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Inc. announced that David Goeddel has resigned from its board of directors and all board committees, effective January 26, 2026, following his retirement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDLB0GKk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","TNYA"],"gpt_icon":0},{"id":"2592618577","title":"Tenaya Therapeutics Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2592618577","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592618577?lang=en_us&edition=fundamental","pubTime":"2025-12-19 02:36","pubTimestamp":1766082960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TNYA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 18, 2025 13:36 ET (18:36 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNYA"],"gpt_icon":0},{"id":"2591658591","title":"Tenaya Therapeutics (TNYA) Is Down 39.7% After FDA Lifts TN-201 Hold and Trial Updates - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2591658591","media":"Simply Wall St.","labels":["policyRegulatory","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591658591?lang=en_us&edition=fundamental","pubTime":"2025-12-13 23:35","pubTimestamp":1765640158,"startTime":"0","endTime":"0","summary":"Earlier this month, Tenaya Therapeutics reported that the FDA lifted the clinical hold on its MyPEAK-1 Phase 1b/2a trial of TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and released encouraging interim Phase 1b/2 data for TN-401 in arrhythmogenic right ventricular cardiomyopathy, while also completing a US$60,000,000 composite units offering.\nTogether, the resumed TN-201 trial and early TN-401 signals highlight Tenaya’s push to use AAV9-based gene therapies to address inherited...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tnya/tenaya-therapeutics/news/tenaya-therapeutics-tnya-is-down-397-after-fda-lifts-tn-201","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tnya/tenaya-therapeutics/news/tenaya-therapeutics-tnya-is-down-397-after-fda-lifts-tn-201","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TNYA","BK4139","BK4539"],"gpt_icon":0},{"id":"2591468687","title":"Tenaya Stock Plunges After $60 Million Equity Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2591468687","media":"Benzinga_recent_news","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591468687?lang=en_us&edition=fundamental","pubTime":"2025-12-13 02:56","pubTimestamp":1765565760,"startTime":"0","endTime":"0","summary":"Heart disease-focused Tenaya Therapeutics falls on high volume after pricing a $60 million offering and releasing new TN-401 data, while the FDA clears the TN-201 trial hold.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/12/Stock-Market-Remains-Largely-Unfazed-Wit.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/12/Stock-Market-Remains-Largely-Unfazed-Wit.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49371243/tenaya-stock-plunges-after-60-million-equity-offering","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49371243/tenaya-stock-plunges-after-60-million-equity-offering","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4585","BK4539","ACM","EQR","BK4516","BK4588","BK4139","LU1861219969.SGD","LU2244417387.USD","LU0124676726.USD","LU0187121727.USD","LU2308191902.HKD","LU2238339852.HKD","LU2298064838.USD","LU2360107325.USD","BK4129","LU1939255532.USD","LU0689626769.HKD","LU1861214812.USD","TNYA","BK4215"],"gpt_icon":0},{"id":"2590501725","title":"Tenaya Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $3 From $5","url":"https://stock-news.laohu8.com/highlight/detail?id=2590501725","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590501725?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:48","pubTimestamp":1765547301,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nAZN4RDLMN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TNYA","BK4539"],"gpt_icon":0},{"id":"2590501850","title":"Tenaya Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2590501850","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590501850?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:20","pubTimestamp":1765545600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TNYA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2025 08:20 ET (13:20 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNYA"],"gpt_icon":0},{"id":"2590527558","title":"Tenaya Therapeutics Announces Pricing of Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590527558","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590527558?lang=en_us&edition=fundamental","pubTime":"2025-12-12 13:16","pubTimestamp":1765516613,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA4LQTPC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TNYA","BK4539"],"gpt_icon":0},{"id":"2590544071","title":"BUZZ-Tenaya Therapeutics slides after launching stock offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590544071","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590544071?lang=en_us&edition=fundamental","pubTime":"2025-12-12 06:25","pubTimestamp":1765491937,"startTime":"0","endTime":"0","summary":"BUZZ-Tenaya Therapeutics slides after launching stock offering** Drug developer Tenaya Therapeutics' TNYA.O shares slide 12.5% to $1.19 in extended trading** TNYA unveils public offering of common stock and warrants; size not disclosed** Leerink Partners and Piper Sandler are joint bookrunning managers for offering ** Separately, TNYA announces data from early trial for experimental gene therapy in rare heart condition** TNYA has 166.5 million outstanding shares for $233 million market cap, per LSEG data** All eight brokerages covering the stock rate it \"buy\" or higher; median PT $5 - data compiled by LSEG** As of last close, TNYA stock down 4.9% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nL6N3XH135:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4207","TNYA","MNSH","BK4139","BK4127","PIPR"],"gpt_icon":0},{"id":"2590491445","title":"BRIEF-Tenaya Therapeutics says early trial shows promise for gene therapy in rare heart condition","url":"https://stock-news.laohu8.com/highlight/detail?id=2590491445","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590491445?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:05","pubTimestamp":1765487138,"startTime":"0","endTime":"0","summary":"BRIEF-Tenaya Therapeutics says early trial shows promise for gene therapy in rare heart condition Dec 11 (Reuters) - Tenaya Therapeutics Inc TNYA.O:TENAYA THERAPEUTICS REPORTS POSITIVE INTERIM DATA FR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA542KXW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TNYA","BK4539"],"gpt_icon":0},{"id":"2590454151","title":"Tenaya Therapeutics Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590454151","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590454151?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:02","pubTimestamp":1765486920,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Dec.  11, 2025  (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potent","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3204290/0/en/Tenaya-Therapeutics-Announces-Proposed-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HCM","BK4588","BK4007","BK4539","BK4531","TNYA","BK4585"],"gpt_icon":0},{"id":"2590354996","title":"FDA Lifts Clinical Hold on Tenaya Therapeutics’ MyPEAK-1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590354996","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590354996?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486878,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Inc. has announced that the U.S. Food and Drug Administration  has lifted the clinical hold on its MyPEAK-1 Phase 1b/2a clinical trial of TN-201, a gene therapy being developed for the treatment of MYBPC3-associated hypertrophic cardiomyopathy. The decision follows Tenaya's successful resolution of all FDA concerns related to the hold. The company is now implementing protocol amendments agreed upon with the FDA and plans to resume dosing in collaboration with clinical sites. No new safety issues have been identified, and Tenaya does not expect the hold to affect its data milestones or development timelines.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc. published the original content used to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL4T58RL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","LU2210149790.SGD","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014039.USD","LU2095319765.USD","SG9999014021.USD","SG9999014005.SGD","IE00BGHQF748.EUR","BK4539","IE00B3QW5Z07.USD","LU0314104364.USD","NDAQ","TNYA","BK4585","BK4112","BK4139","BK4588","IE00B64PRP62.GBP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tenayatherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0748},{"period":"1month","weight":0.0024},{"period":"3month","weight":-0.5869},{"period":"6month","weight":-0.1889},{"period":"1year","weight":-0.4984},{"period":"ytd","weight":-0.0131}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0044},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.068},{"period":"1year","weight":0.1339},{"period":"ytd","weight":-0.0064}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.071309},{"month":2,"riseRate":0.25,"avgChangeRate":0.060915},{"month":3,"riseRate":0.25,"avgChangeRate":-0.154481},{"month":4,"riseRate":0.25,"avgChangeRate":0.087213},{"month":5,"riseRate":0.25,"avgChangeRate":-0.005732},{"month":6,"riseRate":0.25,"avgChangeRate":-0.069846},{"month":7,"riseRate":0.5,"avgChangeRate":-0.023292},{"month":8,"riseRate":0.4,"avgChangeRate":0.09529},{"month":9,"riseRate":0.4,"avgChangeRate":-0.101393},{"month":10,"riseRate":0.2,"avgChangeRate":-0.046678},{"month":11,"riseRate":0.4,"avgChangeRate":0.123533},{"month":12,"riseRate":0.2,"avgChangeRate":-0.128991}],"exchange":"NASDAQ","name":"Tenaya Therapeutics Inc","nameEN":"Tenaya Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tenaya Therapeutics Inc(TNYA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tenaya Therapeutics Inc(TNYA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tenaya Therapeutics Inc,TNYA,Tenaya Therapeutics Inc股票,Tenaya Therapeutics Inc股票老虎,Tenaya Therapeutics Inc股票老虎国际,Tenaya Therapeutics Inc行情,Tenaya Therapeutics Inc股票行情,Tenaya Therapeutics Inc股价,Tenaya Therapeutics Inc股市,Tenaya Therapeutics Inc股票价格,Tenaya Therapeutics Inc股票交易,Tenaya Therapeutics Inc股票购买,Tenaya Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tenaya Therapeutics Inc(TNYA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tenaya Therapeutics Inc(TNYA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}